IDH1 and infantile convulsions and choreoathetosis: Following the positive results of the phase III ClarIDHy, the IDH1 inhibitor ivosidenib has been approved by both the EMA and FDA for patients with IDH1 mutant locally advanced or metastatic iCCA who have been treated with at least one prior line of systemic therapy [9,10,11].